Cargando…

Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics

Gliomas are a heterogenous group of central nervous system tumors with different outcomes and different therapeutic needs. Glioblastoma, the most common subtype in adults, has a very poor prognosis and disabling consequences. The World Health Organization (WHO) classification specifies that the typi...

Descripción completa

Detalles Bibliográficos
Autores principales: Balana, Carmen, Castañer, Sara, Carrato, Cristina, Moran, Teresa, Lopez-Paradís, Assumpció, Domenech, Marta, Hernandez, Ainhoa, Puig, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177999/
https://www.ncbi.nlm.nih.gov/pubmed/35693015
http://dx.doi.org/10.3389/fneur.2022.865171
_version_ 1784722962188861440
author Balana, Carmen
Castañer, Sara
Carrato, Cristina
Moran, Teresa
Lopez-Paradís, Assumpció
Domenech, Marta
Hernandez, Ainhoa
Puig, Josep
author_facet Balana, Carmen
Castañer, Sara
Carrato, Cristina
Moran, Teresa
Lopez-Paradís, Assumpció
Domenech, Marta
Hernandez, Ainhoa
Puig, Josep
author_sort Balana, Carmen
collection PubMed
description Gliomas are a heterogenous group of central nervous system tumors with different outcomes and different therapeutic needs. Glioblastoma, the most common subtype in adults, has a very poor prognosis and disabling consequences. The World Health Organization (WHO) classification specifies that the typing and grading of gliomas should include molecular markers. The molecular characterization of gliomas has implications for prognosis, treatment planning, and prediction of treatment response. At present, gliomas are diagnosed via tumor resection or biopsy, which are always invasive and frequently risky methods. In recent years, however, substantial advances have been made in developing different methods for the molecular characterization of tumors through the analysis of products shed in body fluids. Known as liquid biopsies, these analyses can potentially provide diagnostic and prognostic information, guidance on choice of treatment, and real-time information on tumor status. In addition, magnetic resonance imaging (MRI) is another good source of tumor data; radiomics and radiogenomics can link the imaging phenotypes to gene expression patterns and provide insights to tumor biology and underlying molecular signatures. Machine and deep learning and computational techniques can also use quantitative imaging features to non-invasively detect genetic mutations. The key molecular information obtained with liquid biopsies and radiogenomics can be useful not only in the diagnosis of gliomas but can also help predict response to specific treatments and provide guidelines for personalized medicine. In this article, we review the available data on the molecular characterization of gliomas using the non-invasive methods of liquid biopsy and MRI and suggest that these tools could be used in the future for the preoperative diagnosis of gliomas.
format Online
Article
Text
id pubmed-9177999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91779992022-06-10 Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics Balana, Carmen Castañer, Sara Carrato, Cristina Moran, Teresa Lopez-Paradís, Assumpció Domenech, Marta Hernandez, Ainhoa Puig, Josep Front Neurol Neurology Gliomas are a heterogenous group of central nervous system tumors with different outcomes and different therapeutic needs. Glioblastoma, the most common subtype in adults, has a very poor prognosis and disabling consequences. The World Health Organization (WHO) classification specifies that the typing and grading of gliomas should include molecular markers. The molecular characterization of gliomas has implications for prognosis, treatment planning, and prediction of treatment response. At present, gliomas are diagnosed via tumor resection or biopsy, which are always invasive and frequently risky methods. In recent years, however, substantial advances have been made in developing different methods for the molecular characterization of tumors through the analysis of products shed in body fluids. Known as liquid biopsies, these analyses can potentially provide diagnostic and prognostic information, guidance on choice of treatment, and real-time information on tumor status. In addition, magnetic resonance imaging (MRI) is another good source of tumor data; radiomics and radiogenomics can link the imaging phenotypes to gene expression patterns and provide insights to tumor biology and underlying molecular signatures. Machine and deep learning and computational techniques can also use quantitative imaging features to non-invasively detect genetic mutations. The key molecular information obtained with liquid biopsies and radiogenomics can be useful not only in the diagnosis of gliomas but can also help predict response to specific treatments and provide guidelines for personalized medicine. In this article, we review the available data on the molecular characterization of gliomas using the non-invasive methods of liquid biopsy and MRI and suggest that these tools could be used in the future for the preoperative diagnosis of gliomas. Frontiers Media S.A. 2022-05-26 /pmc/articles/PMC9177999/ /pubmed/35693015 http://dx.doi.org/10.3389/fneur.2022.865171 Text en Copyright © 2022 Balana, Castañer, Carrato, Moran, Lopez-Paradís, Domenech, Hernandez and Puig. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Balana, Carmen
Castañer, Sara
Carrato, Cristina
Moran, Teresa
Lopez-Paradís, Assumpció
Domenech, Marta
Hernandez, Ainhoa
Puig, Josep
Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
title Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
title_full Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
title_fullStr Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
title_full_unstemmed Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
title_short Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
title_sort preoperative diagnosis and molecular characterization of gliomas with liquid biopsy and radiogenomics
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177999/
https://www.ncbi.nlm.nih.gov/pubmed/35693015
http://dx.doi.org/10.3389/fneur.2022.865171
work_keys_str_mv AT balanacarmen preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT castanersara preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT carratocristina preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT moranteresa preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT lopezparadisassumpcio preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT domenechmarta preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT hernandezainhoa preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics
AT puigjosep preoperativediagnosisandmolecularcharacterizationofgliomaswithliquidbiopsyandradiogenomics